Georgetown University

🇬🇹Guatemala

Country: 🇬🇹Guatemala

Ownership: Private

Established: 1789-01-23

Employees: 5K

Market Cap: -

Website: http://www.georgetown.edu

Clinical Trials

A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Temozolomide
Drug: ABT-888

First Posted Date: 2010-01-18

Last Posted Date: 2019-04-02

Lead Sponsor: Georgetown University

Target Recruit Count: 75

Registration Number: NCT01051596

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer

Withdrawn

Conditions: Colorectal Cancer

First Posted Date: 2009-11-13

Last Posted Date: 2011-03-24

Lead Sponsor: Georgetown University

Registration Number: NCT01012804

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States

Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Ofatumumab and Bendamustine

First Posted Date: 2009-11-10

Last Posted Date: 2015-12-15

Lead Sponsor: Georgetown University

Target Recruit Count: 10

Registration Number: NCT01010568

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States

Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients

Phase 4

Completed

Conditions: Hepatitis B

Interventions: Procedure: glucose monitoring before and after HepaGam B administration
Biological: HepaGam B (Hepatitis B Immune Globulin (HBIG))

First Posted Date: 2009-10-20

Last Posted Date: 2015-09-28

Lead Sponsor: Georgetown University

Target Recruit Count: 5

Registration Number: NCT00998426

Locations: 🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States

Albumin for Intracerebral Hemorrhage Intervention

Phase 2

Terminated

Conditions: Intracerebral Hemorrhage

Interventions: Drug: Placebo
Drug: Albumin
Procedure: Brain MRI with and without contrast

First Posted Date: 2009-10-07

Last Posted Date: 2014-08-29

Lead Sponsor: Georgetown University

Target Recruit Count: 14

Registration Number: NCT00990509

Locations: 🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States

Sunitinib and Capecitabine for First Line Colon Cancer

Phase 2

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: sunitinib and capecitabine

First Posted Date: 2009-08-19

Last Posted Date: 2018-04-03

Lead Sponsor: Georgetown University

Target Recruit Count: 50

Registration Number: NCT00961571

Locations: 🇺🇸
Lombardi Cancer Center at Georgetown University, Washington, District of Columbia, United States

Testing of Computer Aided Detection Software for Riverain Medical Group

Completed

Conditions: Lung Cancer

Interventions: Behavioral: Software

First Posted Date: 2009-05-21

Last Posted Date: 2014-09-01

Lead Sponsor: Georgetown University

Target Recruit Count: 15

Registration Number: NCT00906789

Locations: 🇺🇸
ISIS Imaging Science Research Center, Georgetown University, Washington, District of Columbia, United States

Low Dose Cyclosporin and Methotrexate Therapy in Diabetes

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: cyclosporin and methotrexate

First Posted Date: 2009-05-20

Last Posted Date: 2011-04-13

Lead Sponsor: Georgetown University

Target Recruit Count: 8

Registration Number: NCT00905073

Locations: 🇺🇸
Georgetown University, Washington DC, District of Columbia, United States

Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast

Terminated

Conditions: Breast Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2018-04-13

Lead Sponsor: Georgetown University

Target Recruit Count: 55

Registration Number: NCT00898937

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States

Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

Phase 2

Terminated

Conditions: Pancreas Cancer

Interventions: Drug: Lapatinib and Capecitabine

First Posted Date: 2009-04-15

Last Posted Date: 2017-03-06

Lead Sponsor: Georgetown University

Target Recruit Count: 17

Registration Number: NCT00881621

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy